そう痒症治療薬市場：治療法、投与経路、適応疾患、患者属性、流通チャネル、エンドユーザー別-2025-2030年世界予測

そう痒症治療薬市場の2024年の市場規模は59億3,000万米ドルで、2025年にはCAGR 5.47%で62億4,000万米ドルに成長し、2030年には81億7,000万米ドルに達すると予測されています。

近年、生物医学研究の急速な進展と慢性的なかゆみを引き起こす根本的なメカニズムの理解の深まりにより、そう痒症治療薬の分野は大きな変貌を遂げています。歴史的に、そう痒症の治療は対症療法が中心であり、根本的な原因に対処することなく、一時的な緩和をもたらす第一選択療法に頼っていました。しかし現在では、新規治療薬と革新的な治療パラダイムの合流により、治療アプローチが再定義されています。最近の科学的進歩により、そう痒症をより細かく分類できるようになり、特定の疾患プロセスに対処する標的療法の開発が可能になりました。この進化する情勢は、臨床的革新、患者の期待、規制状況の相互作用によって特徴づけられており、これらはすべて、長い間持続する痒みの不快感に耐えてきた患者のQOL向上につながるものです。ヘルスケア・プロバイダーや意思決定者が、症状としてのそう痒症の複雑さや様々な皮膚科疾患への影響をますます認識するようになり、研究や洗練された臨床戦略への投資意欲が高まっています。さらに、技術の進歩と新たな生物学的製剤との融合により、症状の管理に重点を置くだけでなく、症状の分子的基盤も標的とする新たな時代への道が開かれつつあります。本サマリーでは、変革を推進する力、理解を深めるセグメンテーションの洞察、掻痒症治療薬におけるパラダイムの転換を利害関係者が活用するための戦略的提言について概説します。

進化する市場力学と治療における変革的シフト

現在、そう痒症治療薬市場は、治療ランドスケープ、臨床アプローチ、患者管理方法を再定義する変革的なシフトを経験しています。先駆的な研究と先進的なバイオテクノロジー製品の開発が市場力学を変化させ、精密医療と個別化治療プロトコルに焦点を当てた新世代の治療法の到来を告げています。この変化は、創薬と開発における最先端技術の統合によるところが大きく、これにより、個々の患者のプロファイルに合わせた、より迅速で的を絞った介入が可能になりました。規制当局もまた、迅速な承認に対応するためにその枠組みを適応させており、この分野における技術革新にさらに拍車をかけています。同時に、患者中心の技術の出現は、迅速な救済を提供するだけでなく、長期的な疾患管理とケアの質の向上をも考慮した治療法に対する需要を増大させています。新規分子や再利用薬を含む進化する治療法は、従来のアプローチと比較して有効性と安全性のプロファイルが向上していることを実証する強固な臨床試験によって支えられています。さらに、遠隔医療やデジタル・ヘルス・ソリューションへのシフトは、これらの新規治療へのアクセス性を補い、臨床の進歩が実際の治療結果に効果的に反映されることを保証しています。市場勢力と技術的進歩が治療情勢の再構築を続ける中、利害関係者は、こうした大きな変化の中で競争力を維持するために、従来の治療モデルを見直し、戦略的協力関係を促進する必要性が高まっています。

多角的な市場セグメンテーションから得られる洞察

そう痒症治療薬市場を包括的に分析することで、治療戦略のニュアンスや患者の嗜好を理解する上で極めて重要なセグメンテーションの洞察が明らかになります。さまざまな治療法にわたる市場を調査することで、治療法の進化が抗ヒスタミン薬、生物学的製剤、カルシニューリン阻害薬、コルチコステロイド、免疫抑制薬など幅広い選択肢に及んでいることが明らかになります。各治療薬にはそれぞれ異なる利点があり、そう痒症のさまざまな側面に対応するため、オーダーメイドの治療プロトコールや専門的な患者ケアが可能となります。治療薬には注射剤、経口剤、外用剤があり、それぞれ症状の重症度や性質に応じてさまざまな利点があるため、投与経路は市場をさらに多様化しています。適応症の検討では、アレルギー性接触皮膚炎、アトピー性皮膚炎、皮膚T細胞リンパ腫、蕁麻疹に大きな注目が集まっており、それぞれの適応症が独自の課題をもたらし、カスタマイズされた治療アプローチを必要としています。治療レジメンは成人、老人、小児患者のさまざまなニーズに対応するよう特別に設計されているため、患者の属性も市場展望を形成する上で不可欠な役割を果たしています。さらに、病院薬局、オンライン薬局、小売薬局などの流通チャネルは、治療薬へのアクセスや採用に大きく影響します。診療所、皮膚科センター、在宅医療の現場、病院を含むエンドユーザーのスペクトルは、多様な臨床およびロジスティクスの課題を満たす的を絞った介入を提供することの重要性をさらに強調しています。これらのセグメンテーション基準を総合的に分析すると、戦略的意思決定、資金配分、ターゲットとする患者グループのニーズにより合致した次世代治療薬の開発に役立つ豊富な洞察が得られます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界的に皮膚疾患の有病率が増加
    • 皮膚の健康に関する意識の高まりと早期診断・治療への傾向
    • 世界のヘルスケアインフラの拡大
  • 抑制要因
    • 発展途上地域における掻痒症の認識と診断の限界
  • 機会
    • 新規掻痒薬開発に向けた研究開発活動の急増
    • 掻痒の治療戦略の進歩
  • 課題
    • 医薬品および治療法の承認に関する厳格な規制枠組み
• 市場セグメンテーション分析
  • 治療法：強力な抗炎症作用を持つコルチコステロイドが好まれる傾向が高まっている
  • エンドユーザー：クリニックや皮膚科センターにおける掻痒治療薬の採用拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 そう痒症治療薬市場：セラピー別

• 抗ヒスタミン薬
• 生物学的製剤
• カルシニューリン阻害剤
• コルチコステロイド
• 免疫抑制剤

第7章 そう痒症治療薬市場：投与経路別

• 注射剤
• オーラル
• トピック

第8章 そう痒症治療薬市場：疾患適応症別

• アレルギー性接触皮膚炎
• アトピー性皮膚炎
• 皮膚T細胞
• 蕁麻疹

第9章 そう痒症治療薬市場患者の人口統計別

• 成人患者
• 高齢患者
• 小児患者

第10章 そう痒症治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 そう痒症治療薬市場：エンドユーザー別

• クリニック
• 皮膚科センター
• 在宅ケア設定
• 病院

第12章 南北アメリカのそう痒症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域のそう痒症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカのそう痒症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Asana BioSciences, LLC
• Astellas Pharma Inc.
• Avior Bio Inc.
• Bausch Health Companies Inc.
• Bayer AG
• Cara Therapeutics Inc.
• Eli Lilly and Company
• EPI Health LLC by Novan, Inc.
• Escient Pharmaceuticals by Incyte Corporation
• Evelo Biosciences, Inc.
• Galderma S.A.
• GlaxoSmithKline plc
• LEO Pharma A/S
• Mallinckrodt plc
• MC2 Therapeutics A/S
• Mirum Pharmaceuticals, Inc.
• NeRRe Therapeutics Ltd
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Toray Industries, Inc.
• Trevi Therapeutics, Inc
• Vanda Pharmaceuticals Inc.
• Viatris Inc.

LIST OF FIGURES

• FIGURE 1. PRURITUS THERAPEUTICS MARKET MULTI-CURRENCY
• FIGURE 2. PRURITUS THERAPEUTICS MARKET MULTI-LANGUAGE
• FIGURE 3. PRURITUS THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 4. PRURITUS THERAPEUTICS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 19. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 23. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 28. PRURITUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 29. PRURITUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. PRURITUS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PRURITUS THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CALCINEURIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ALLERGIC CONTACT DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ATOPIC DERMATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CUTANEOUS T-CELL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY URTICARIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY DERMATOLOGY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL PRURITUS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 55. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 56. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 57. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 58. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. CANADA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES PRURITUS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 87. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 88. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 89. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 90. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. CHINA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 93. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 96. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. INDIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. INDONESIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. JAPAN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. MALAYSIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. PHILIPPINES PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. SINGAPORE PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. TAIWAN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. THAILAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 151. VIETNAM PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. DENMARK PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 170. EGYPT PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 176. FINLAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. FRANCE PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. GERMANY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. ISRAEL PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 195. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 196. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 197. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 198. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 199. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 200. ITALY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 206. NETHERLANDS PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 212. NIGERIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 218. NORWAY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 219. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 220. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 221. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 222. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 223. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 224. POLAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 225. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 226. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 227. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 228. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 229. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 230. QATAR PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 236. RUSSIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 242. SAUDI ARABIA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH AFRICA PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 254. SPAIN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 260. SWEDEN PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 266. SWITZERLAND PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 272. TURKEY PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 284. UNITED KINGDOM PRURITUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 285. PRURITUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 286. PRURITUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

The Pruritus Therapeutics Market was valued at USD 5.93 billion in 2024 and is projected to grow to USD 6.24 billion in 2025, with a CAGR of 5.47%, reaching USD 8.17 billion by 2030.

In recent years, the field of pruritus therapeutics has undergone a significant transformation, fueled by rapid advancements in biomedical research and an increasing understanding of the underlying mechanisms that drive chronic itch. Historically, the management of pruritus was largely symptomatic, relying on front-line therapies to offer temporary relief without addressing the fundamental causes. Today, however, a confluence of novel therapeutic agents and innovative treatment paradigms has redefined the approach to care. Recent scientific breakthroughs have enabled a more granular classification of pruritic conditions, permitting the development of targeted therapies that address specific disease processes. This evolving landscape is marked by an interplay between clinical innovation, patient expectations, and regulatory momentum, all leading to improved quality of life for patients who have long endured the discomfort of persistent itch. As healthcare providers and decision-makers increasingly recognize the complexity of pruritus as a symptom and its impact on various dermatological conditions, there is a growing impetus to invest in research and refined clinical strategies. Moreover, the convergence of technological advancement with emerging biologics has paved the way for a new era that not only emphasizes symptom management but also targets the molecular underpinnings of the condition. This introductory summary outlines the forces driving transformation, the segmentation insights that deepen our understanding, and the strategic recommendations poised to help stakeholders capitalize on the shifting paradigms in pruritus therapeutics.

Evolving Market Dynamics and Transformative Shifts in Therapeutics

The market for pruritus therapeutics is currently experiencing transformative shifts that are redefining treatment landscapes, clinical approaches, and patient management practices. Pioneering research and the development of advanced biotechnological products have altered the market dynamics, ushering in a new generation of therapies that focus on precision medicine and personalized treatment protocols. This shift is largely attributable to the integration of cutting-edge technologies in drug discovery and development, which enables faster, more targeted interventions that can be tailored to individual patient profiles. Regulatory bodies have also adapted their frameworks to accommodate expedited approvals, further fueling innovation in the space. Concurrently, the emergence of patient-centric technologies has amplified the demand for therapies that not only provide rapid relief but also account for long-term disease management and improved quality of care. The evolving therapeutic modalities, which include novel molecules and repurposed drugs, are supported by robust clinical trials demonstrating enhanced efficacy and safety profiles compared to traditional approaches. Furthermore, the shift towards telemedicine and digital health solutions has supplemented the accessibility of these novel treatments, ensuring that clinical advances are effectively translated into real-world outcomes. As market forces and technological advancements continue to reshape the therapeutic landscape, stakeholders are increasingly called to reassess traditional treatment models and foster strategic collaborations to remain competitive amid these sweeping changes.

Insights Derived from Multi-Dimensional Market Segmentation

A comprehensive analysis of the pruritus therapeutics market reveals critical segmentation insights that are pivotal for understanding the nuances of treatment strategies and patient preferences. By studying the market across various therapies, it becomes clear that the evolution in treatment modalities spans a range of options including antihistamines, biologics, calcineurin inhibitors, corticosteroids, and immunosuppressants. Each therapeutic category offers distinct benefits and addresses different aspects of pruritic conditions, enabling tailored treatment protocols and specialized patient care. The route of administration further diversifies the market, as treatments are delivered via injectable, oral, and topical formulations, each offering its own set of advantages depending on the severity and nature of the condition. In examining disease indications, significant attention is given to allergic contact dermatitis, atopic dermatitis, cutaneous T-cell lymphoma, and urticaria, with each indication providing unique challenges and requiring customized therapeutic approaches. Patient demographics also play an integral role in shaping the market landscape, as treatment regimens are specifically designed to accommodate the varying needs of adult, geriatric, and pediatric patients. Additionally, distribution channels such as hospital pharmacies, online pharmacies, and retail pharmacies greatly influence access to and adoption of therapeutics. The end-user spectrum, which includes clinics, dermatology centers, homecare settings, and hospitals, further underscores the importance of delivering targeted interventions that meet diverse clinical and logistical challenges. These segmentation criteria, when analyzed together, offer a rich tapestry of insights that inform strategic decision-making, funding allocation, and the development of next-generation therapeutic products that are better aligned with the needs of targeted patient groups.

Based on Therapy, market is studied across Antihistamines, Biologics, Calcineurin inhibitors, Corticosteroids, and Immunosuppressant.

Based on Route of Administration, market is studied across Injectable, Oral, and Topical.

Based on Disease Indication, market is studied across Allergic Contact Dermatitis, Atopic Dermatitis, Cutaneous T-cell, and Urticaria.

Based on Patient Demographics, market is studied across Adult Patients, Geriatric Patients, and Pediatric Patients.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Based on End-User, market is studied across Clinics, Dermatology Centers, Homecare Settings, and Hospitals.

Comprehensive Regional Analysis Across Global Markets

Geographical insights into the pruritus therapeutics market offer a deeper understanding of regional variations in clinical practice patterns, regulatory environments, and patient demographics. In the Americas, dynamic market forces are driven by substantial investments in research and development, robust healthcare infrastructure, and a high level of patient awareness regarding modern therapeutic options. These factors have stimulated rapid growth in demand for innovative treatments. Shifting focus to the Europe, Middle East & Africa region, there is a clear emphasis on stringent regulatory standards and a balanced approach between early adoption of new therapies and cautious market integration. This region is known for its meticulous clinical evaluations and a strong inclination towards evidence-based treatment protocols, ensuring that only therapies with proven efficacy and safety profiles gain wider acceptance. In the Asia-Pacific region, a burgeoning middle class and increasing healthcare expenditures have created fertile ground for the uptake of advanced therapeutics. Yet, this region also faces challenges such as disparate healthcare infrastructures, diverse regulatory landscapes, and significant variations in clinical practice that require a more tailored approach to market entry. Taken together, the regional analysis highlights not only the disparities in market maturity and growth potential but also the opportunities for customized strategies that address the unique challenges and strengths inherent in each region. As market stakeholders consider global expansion, these geographical insights will be instrumental in shaping targeted strategies that leverage regional strengths and address localized challenges effectively.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Competitive Landscape and Strategic Company Initiatives

An in-depth examination of the competitive landscape within pruritus therapeutics reveals a spectrum of innovative companies actively driving market evolution. Key players such as AbbVie Inc., Asana BioSciences, LLC, Astellas Pharma Inc., and Avior Bio Inc. have carved out significant niches through sustained investments in research and novel therapeutic development. Companies like Bausch Health Companies Inc., Bayer AG, and Cara Therapeutics Inc. have further expanded the market by integrating emerging biologics and specialty drugs into their portfolios, addressing complex clinical challenges inherent in pruritic conditions. The market is also shaped by the robust presence of industry giants such as Eli Lilly and Company, Escient Pharmaceuticals by Incyte Corporation, and GlaxoSmithKline plc, whose expansive reach and continuous innovation underscore the competitive drive in therapeutic advancements. Moreover, players like EPI Health LLC by Novan, Inc., Evelo Biosciences, Inc., and Galderma S.A. are key contributors to developing tailored treatments that meet the diverse needs of patients across different demographics and indications. Strategic initiatives undertaken by firms such as LEO Pharma A/S, Mallinckrodt plc, MC2 Therapeutics A/S, and Mirum Pharmaceuticals, Inc. showcase an unwavering focus on clinical excellence and patient-centric innovations. The market dynamics are further enriched by contributions from NeRRe Therapeutics Ltd, Novartis AG, Pfizer Inc., and Regeneron Pharmaceuticals, Inc., which continue to drive the pace of technological advancement and therapeutic efficacy. Additionally, companies like Sanofi S.A., Teva Pharmaceutical Industries Ltd., Toray Industries, Inc., Trevi Therapeutics, Inc., Vanda Pharmaceuticals Inc., and Viatris Inc. actively contribute to a competitive environment that emphasizes collaboration, innovation, and the rapid integration of scientific discoveries into clinical practice. This collective momentum is redefining the strategic landscape, fostering a dynamic ecosystem where relentless innovation and strategic foresight play crucial roles in meeting both current and future market demands.

The report delves into recent significant developments in the Pruritus Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Asana BioSciences, LLC, Astellas Pharma Inc., Avior Bio Inc., Bausch Health Companies Inc., Bayer AG, Cara Therapeutics Inc., Eli Lilly and Company, EPI Health LLC by Novan, Inc., Escient Pharmaceuticals by Incyte Corporation, Evelo Biosciences, Inc., Galderma S.A., GlaxoSmithKline plc, LEO Pharma A/S, Mallinckrodt plc, MC2 Therapeutics A/S, Mirum Pharmaceuticals, Inc., NeRRe Therapeutics Ltd, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Toray Industries, Inc., Trevi Therapeutics, Inc, Vanda Pharmaceuticals Inc., and Viatris Inc.. Strategic Recommendations for Thought Leaders in Therapeutics

For industry leaders looking to gain a competitive advantage in the rapidly evolving market of pruritus therapeutics, strategic foresight and operational agility are essential. First and foremost, investment in research and development should be prioritized, with a focus on pioneering therapies that leverage targeted drug delivery systems and precision medicine. Leaders are encouraged to adopt a proactive approach by establishing strategic partnerships with research institutions and clinical centers to expand the scope of innovative treatment modalities. As the market continues to mature, diversification of product portfolios to include both established therapies and emerging biologics will ensure resilience against market fluctuations. In addition, a deep understanding of patient demographics and evolving clinical needs is crucial; engaging in regular stakeholder consultations and feedback loops will facilitate better alignment of treatment strategies with real-world requirements. Emphasizing digital transformation and telehealth solutions can also enhance patient engagement and adherence to therapy regimens while broadening market reach. Regulatory agility remains a key factor, and leaders should strive to maintain transparent communication channels with regulatory authorities to streamline approval processes for novel drugs. Lastly, competitive intelligence, backed by comprehensive market research, should serve as a cornerstone for strategic planning, enabling organizations to anticipate market trends, effectively allocate resources, and seize growth opportunities in an increasingly dynamic environment.

Summative Insights and Forward-Looking Perspectives

In conclusion, the pruritus therapeutics market is at a pivotal juncture where scientific innovation and strategic vision converge to transform patient care. The evolving landscape, driven by breakthrough research and robust segmentation insights, offers a compelling narrative of progress that extends from advanced therapy options to nuanced regional strategies. The formative insights from multi-dimensional segmentation reveal significant opportunities for tailored interventions while detailed competitive analysis underscores the critical role of leading companies in shaping market direction. Moving forward, continued investment in research, technology, and strategic partnerships will be the linchpin of sustained market growth. Stakeholders who embrace agility and innovation are well-positioned to capitalize on emerging trends, optimize resource allocation, and drive improvements in patient outcomes. The body of insights presented not only highlights the current state of pruritus therapeutics but also provides a forward-looking framework for future market explorations, ensuring that the industry remains responsive to evolving clinical landscapes and patient needs.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of dermatological conditions globally
    • 5.1.1.2. Rising awareness about skin health and inclination toward early diagnosis & treatment
    • 5.1.1.3. Expansion of healthcare infrastructure globally
  • 5.1.2. Restraints
    • 5.1.2.1. Limited awareness and diagnosis of pruritus in underdeveloped regions
  • 5.1.3. Opportunities
    • 5.1.3.1. Surge in research and development activities for the development of novel pruritus drugs
    • 5.1.3.2. Advancements in therapeutic strategies for the treatment of pruritus
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory framework for the approval of drugs and therapies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Therapy: Increasing preference for corticosteroids due to their strong anti-inflammatory properties
  • 5.2.2. End User: Expanding adoption of pruritus-therapeutics in clinics and dermatology centers
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Pruritus Therapeutics Market, by Therapy

• 6.1. Introduction
• 6.2. Antihistamines
• 6.3. Biologics
• 6.4. Calcineurin inhibitors
• 6.5. Corticosteroids
• 6.6. Immunosuppressant

7. Pruritus Therapeutics Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injectable
• 7.3. Oral
• 7.4. Topical

8. Pruritus Therapeutics Market, by Disease Indication

• 8.1. Introduction
• 8.2. Allergic Contact Dermatitis
• 8.3. Atopic Dermatitis
• 8.4. Cutaneous T-cell
• 8.5. Urticaria

9. Pruritus Therapeutics Market, by Patient Demographics

• 9.1. Introduction
• 9.2. Adult Patients
• 9.3. Geriatric Patients
• 9.4. Pediatric Patients

10. Pruritus Therapeutics Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Online Pharmacies
• 10.4. Retail Pharmacies

11. Pruritus Therapeutics Market, by End-User

• 11.1. Introduction
• 11.2. Clinics
• 11.3. Dermatology Centers
• 11.4. Homecare Settings
• 11.5. Hospitals

12. Americas Pruritus Therapeutics Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Pruritus Therapeutics Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Pruritus Therapeutics Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Maruho Co., Ltd. strengthens its position in dermatological care with launch of innovative pruritus treatment, Mitchga
  • 15.3.2. Galderma's nemolizumab advances in pruritus therapeutics with new global filing acceptances
  • 15.3.3. Incyte's strategic acquisition of Escient to advance first-in-class pruritus therapies in inflammation
  • 15.3.4. FDA approval expands treatment options for PFIC patients with Mirum Pharmaceutical's LIVMARLI's oral solution for pruritus relief
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Asana BioSciences, LLC
• 3. Astellas Pharma Inc.
• 4. Avior Bio Inc.
• 5. Bausch Health Companies Inc.
• 6. Bayer AG
• 7. Cara Therapeutics Inc.
• 8. Eli Lilly and Company
• 9. EPI Health LLC by Novan, Inc.
• 10. Escient Pharmaceuticals by Incyte Corporation
• 11. Evelo Biosciences, Inc.
• 12. Galderma S.A.
• 13. GlaxoSmithKline plc
• 14. LEO Pharma A/S
• 15. Mallinckrodt plc
• 16. MC2 Therapeutics A/S
• 17. Mirum Pharmaceuticals, Inc.
• 18. NeRRe Therapeutics Ltd
• 19. Novartis AG
• 20. Pfizer Inc.
• 21. Regeneron Pharmaceuticals, Inc.
• 22. Sanofi S.A.
• 23. Teva Pharmaceutical Industries Ltd.
• 24. Toray Industries, Inc.
• 25. Trevi Therapeutics, Inc
• 26. Vanda Pharmaceuticals Inc.
• 27. Viatris Inc.